1. Home >
  2. M&A >
  3. Venture >
  4. Israel >
  5. Eight Roads Invests In Noogata

Investment Summary

Eight Roads Invests In Noogata

On April 12, 2022, private equity firm Eight Roads invested in information technology company Noogata

Investment Highlights
  • This is Eight Roads’ 31st transaction in the Information Technology sector.
  • This is Eight Roads’ 1st transaction in Israel.
Investment Fate
  • Noogata was sold to a financial buyer in 2025.

Investment Summary
Date 2022-04-12
Target Noogata
Sector Information Technology
Investor(s) Eight Roads
Deal Type Venture

Target

Noogata

Tel Aviv, Israel
Noogata provides no-code artificial intelligence (AI) for enterprises. Its AI platform is built for business users who need to turn their data into actionable insights quickly and easily to drive opportunities, growth, and profit. Noogata delivers the benefits of best-in-class AI for maximum business impact without the complexity and costs of having to develop or maintain your own models. Noogata was founded in 2019 and is based in Tel Aviv, Israel.

Search 215,130 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Eight Roads

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1969
PE ASSETS 11.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 281 of 293
Sector: Information Technology M&A 31 of 31
Type: Venture M&A Deals 255 of 266
Country: Israel M&A 1 of 1
Year: 2022 M&A 12 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-12 Sonosemi

Shenzhen, China

Sonosemi is an emerging energy-based endovascular therapy platform, starting from intravascular lithotripsy technology (IVL) for endovascular calcification treatment. Sonosemi is based in Shenzhen, China.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-19 Checkmate Pharmaceuticals

Cambridge, Massachusetts, United States

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the activation of innate immunity to treat cancer. Checkmate Pharmaceuticals was formed in 2015 and is based in Cambridge, Massachusetts.

Sell $250M
Mergr

Solution for

Product

Company

Legal